How to control the size and morphology of apatite nanocrystals in bone.

B iomineralized materials are highly organized composites with hierarchical structures, in which the basic building blocks (apatite crystals) are generally in the nanometer size range to ensure optimum physical and biological functions (1). The biological mechanisms of tissue development have attracted a great deal of recent attention in fields ranging from biology and chemistry to materials science and bioengineering (2, 3). It is well known that the organic component of bone acts as an important regulator of lattice orientation, particle size, and size distribution in biomineralization processes, but the molecular recognition details at inorganic crystal interfaces are poorly understood (4). Recently, most investigations have been focused on the effects of macromolecules such as carboxylate-rich proteins on hydroxyapatite nucleation and growth because complex interactions and changes of conformation are involved (5, 6). The role of small organic molecules such as citrate was deemphasized and was assumed to be simply that of adsorption on the crystal growth steps, resulting in inhibition of crystal growth (7, 8). However, there is still much to be learned about the mechanisms of crystal size control in biological systems. New insight about the role of citrate is emerging, as illustrated by a study in PNAS (9), in which strongly bound citrate molecules were identified as playing critical roles in interfering with crystal thickening and stabilizing apatite nanocrystal sizes in bone. The report, by Schmidt-Rohr and colleagues (9), focuses on a quantitative analysis of citrate adsorbed on bone surfaces by the use of advanced multi-NMR spectroscopy and distance measurements. It demonstrates that the citrate, strongly immobilized on the surface of bone, accounts for 5.5 wt% of the organic matter in bone. The density of the citrate coverage is approximately one molecule per (2 nm), which implies that approximately one sixth of the available apatite surface area in bone is covered by citrate molecules. The long axes of the citrate molecules are nearly parallel to the apatite surface, with their three carboxylate groups at distances of 0.3–0.45 nm from the apatite surface. The suggested reasons for the ability of the citrate molecules to control the thickness of apatite nanocrystals are the relatively large amounts of citrate in the organic component of bone and the matching of spacings between carboxylate groups in the citrate molecule with those of calcium ions along the apatite c-axis. The impressive new picture proposed for the interaction of citrate molecules with apatite surfaces adds to our understanding of a number of basic problems involved in the complex bone biomineralization process. An understanding of hierarchical biomineral structure construction, size control, and order of self-assembly must involve the roles of organic components of bone such as collagen, carboxylate-rich protein, and citrate molecules in calcium phosphate nucleation and crystal growth. Previously, it was known only that most carboxylate-rich proteins and collagen could promote nucleation by decreasing the induction time (10); citrate molecules inhibit nucleation by interacting with calcium ions (7, 8). However, they can all inhibit crystal growth by binding on the crystal surfaces. Other details, such as the mechanism of size control in vivo, have not been satisfactorily elucidated. Furthermore, there seems to be a predetermined size of the inorganic nanocrystal corresponding to the optimal mechanical property for the biomineral nanocomposite material. Size control mechanisms in biological systems, for example relating to growth initiation and the mechanisms of growth inhibition, are still not clear. On the basis of this unique model of citrate binding to apatite, we can propose mechanisms for crystal size control in bone as follows. Recent investigations of the first-formed mineral phase of bone show that amorphous calcium phosphate (ACP) is a major component, and the question arises as to how citrate influences the early ACP phase formation (11). Generally, in supersaturated calcium phosphate solutions, the relatively stable ACP clusters are formed first (12, 13). At the early stage of nucleation in the presence of citrate, for the small size and amorphous structure of the early clusters, only some citrate molecules can partly bind with the cluster surface, inhibit further aggregation, and increase the induction time, as shown in Fig. 1A. In the later nucleation stage, the ACP clusters become larger because of aggregation, which can be promoted by the presence of noncollagenous protein. At the same time, mineralized collagen fibrils promote the self-assembly of oriented small amorphous clusters on the collagen surfaces (14, 15). At this stage, some unstable tiny prenuclei form within the large amorphous clusters, and the surface area occupied by bound citrate molecules increases Fig. 1. Schematics of nanocrystal size control involving citrate. (A) In the early nucleation stage, citrate can partly bind with ACP clusters and inhibit their further aggregation. (B) In the later nucleation stage, the ACP clusters become larger because of aggregation, which can be promoted by the presence of noncollagenous protein. At this time, some unstable tiny prenuclei form within the larger amorphous clusters, and the surface area density of citrate binding undergoes a small increase. (C) After apatite nanocrystal formation, the (10Ī0) surface is fully covered by citrate due to space matching. The crystal growth in the [10Ī0] direction is inhibited. At the same time, the surface binding with citrate raises the interfacial compatibility between apatite crystals and the collagen layer.